Navigation Links
Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
Date:3/6/2009

- Interim Findings To Be Presented in a Poster Session at the 67th Annual Meeting of the American Academy of Dermatology -

SAN FRANCISCO, March 6 /PRNewswire/ -- Galderma Laboratories, L.P. today announced interim findings from a study of sequential treatment of plaque psoriasis using Clobex(R) (clobetasol propionate) Spray 0.05% followed by treatment with Vectical(TM) (calcitriol) Ointment 3mcg/g. The results of an interim analysis of the data are to be presented in a poster session at the 67th Annual Meeting of the American Academy of Dermatology on March 8th at 10:30 a.m. PT. The poster can be found under reference number 3362.

While both Clobex Spray and Vectical Ointment are indicated for the treatment of plaque psoriasis, this study was conducted to confirm the safety and efficacy of these products when used in a sequential regimen. In this study, Clobex Spray was used in the initial phase of the study to treat moderate to severe plaque psoriasis. For subjects sufficiently clear at the end of 4 weeks, Vectical Ointment was applied twice-daily for 8 weeks. Success was evaluated at week 12 based on Overall Disease Severity (ODS) scores.

The interim results indicate that sequential treatment of plaque psoriasis with Clobex Spray followed by Vectical Ointment is effective in managing plaque psoriasis over a 12-week period. Additionally, the interim results demonstrate that this sequential treatment regimen was well tolerated, with the most commonly reported side effects including mild to moderate pruritus (itching), stinging and burning and telangectasias (small dilated blood vessels near the surface of the skin).(1)

"The recent availability of Vectical Ointment fulfills an important unmet need for patients who do not have access to a steroid-free ointment that can help manage their condition both safely and effectively over the long-term," said Mark Lebwohl, M.D., Department o
'/>"/>

SOURCE Galderma Laboratories, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
(Date:8/18/2014)... Calif. , Aug. 18, 2014 ... therapeutics to treat infectious diseases, has announced intentions ... the treatment of the current Ebola Virus outbreak ... the use of GBV006, a combination of Food ... established compassionate use regulatory pathway.  The discovery of ...
(Date:8/18/2014)... 2014  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... Tomasello as its Chief Commercial Officer.  Ms. Cline ... of the Americas, Hematology and Oncology, for the Celgene ... Prior to joining Celgene, Ms. Cline Tomasello was the ... Genentech, where she was responsible for over $1.7 billion ...
Breaking Medicine Technology:Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 2Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 3Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 4Pharmacyclics Appoints Chief Commercial Officer 2Pharmacyclics Appoints Chief Commercial Officer 3Pharmacyclics Appoints Chief Commercial Officer 4
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:8/19/2014)... LunaDress, a popular supplier of fashionable ... ladies, is now providing a discount of up to ... company’s cheap white prom outfits are available in different ... outfits. , There are over 400 cheap white ... the special offer is valid until August 29, 2014. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... 2014 The National Cannabis Industry ... Southwest CannaBusiness Symposium on Saturday, August 23, from ... in Las Vegas. , Featuring keynotes by U.S. Representative ... (D-Las Vegas), the event will also include in-depth discussions ... NCIA is doing federally to advance a legitimate and ...
(Date:8/19/2014)... Drews Dental Services is proud to announce the recent election ... Maine Dental Association (MDA). After serving on the Executive Board ... been sworn in to his new position. , Dr. Drews ... and being a part of the ADA House of Delegates ... 2015. He plans to advocate for the profession of dentistry ...
(Date:8/19/2014)... Tara Haelle HealthDay ... -- Kidney injury can be added to the list ... medications often prescribed to treat behavioral symptoms of dementia ... (Seroquel), risperidone (Risperdal) and olanzapine (Zyprexa) are approved by ... disorder, schizophrenia and other serious mental disorders. They are ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:SATURDAY IN LAS VEGAS: U.S. Rep. Dina Titus, State Sen. Tick Segerblom Keynote National Cannabis Industry Association Southwest CannaBusiness Symposium 2Health News:Dr. Drews Elected VP of Maine Dental Association 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... Five former directors of the Population and Reproductive Health ... (USAID) today urged the new Obama administration to move ... . The former directors issued a joint report, ... Assistance, as Barack Obama takes office as president. ...
... K. Shinseki took the oath of office today as ... leadership of the Department of Veterans Affairs following Tuesday,s ... from my first day in office is to make ... focused on the Nation,s Veterans as its clients," Shinseki ...
... 21 The following statement can be attributed ... BlueCross:"Capital BlueCross has consistently said two things: We ... other merger. But we have urged public policy ... this proposed merger without conditions, because without conditions ...
... low levels of sexual desire, often as a result of ... physical symptoms such as back pain and memory problems than ... new study by researchers at the University of North Carolina ... study, published recently as an online early view article in ...
... history was made 10 years ago, greatly impacting the ... when a team of surgeons performed the first hand ... procedure, also called composite tissue allotransplantation, criticized by some ... in the world of organ transplantation, has continued to ...
... IDEXX Laboratories, Inc. (Nasdaq: IDXX ), has scheduled ... results for Friday, January 30, at approximately 7:00 a.m. (eastern). ... 9:00 a.m. (eastern) on that day. Individuals can access a ... the IDEXX Web site, www.idexx.com . An archived edition ...
Cached Medicine News:Health News:Five Former USAID Officials Ask Obama for Leadership on Family Planning 2Health News:Shinseki Sworn In, Vows 21st Century Service to Veterans 2Health News:Capital Blue Cross Issues Statement on Withdrawal of Merger 2Health News:UNC study: Postmenopausal women's loss of sexual desire affects health, quality of life 2Health News:Hand Transplantation Marks Historical 10-Year Milestone 2Health News:Hand Transplantation Marks Historical 10-Year Milestone 3Health News:Hand Transplantation Marks Historical 10-Year Milestone 4
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: